KDX1381
KDX1381 is a bivalent CK2α inhibitor (IC50: 17 nM, KD: 54 nM) . KDX1381 has antitumor activity in mouse 786-O and A375 tumor xenograft models. KDX1381 combined with VEGFR inhibitors or DNA damaging agents enhances antitumor efficacy in mouse hepatocellular carcinoma and glioma models[1].
Product Specifications
CAS Number
2757728-47-3
UNSPSC
12352005
Target
Casein Kinase
Related Pathways
Cell Cycle/DNA Damage; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
FC1=CC=CC(O)=C1C2=CC=C(S(NCCN3CCC(CN4C=C(C5=C(C(C)=O)NC6=C5C=C(F)C=C6)N=N4)CC3)(=O)=O)C=C2
Molecular Formula
C32H32F2N6O4S
Molecular Weight
634.70
References & Citations
[1]Marlhoux L, et al. Discovery of KDX1381, a Bivalent CK2α Inhibitor for the Treatment of Solid Tumors as a Single Agent or in Combination. J Med Chem. 2025 Jun 26;68 (12) :12819-12844.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CK2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC041902-500 1x 500 µL
Nucleophosmin (Acute Myeloid Leukemia Marker) (NPM1/1902), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
